And the winner is …. Laurel Schunselaar
Laurel Schunselaar (LUMC) is the winner of the Paul Janssen Futurelab Nomination Letter 2019 for the best clinical proposal entitled ‘A phase Ib dose finding study with aclarubicin in patients with metastasized uveal melanoma.’ The letter will be submitted with the research proposal to ZonMw’s Rational Pharmacotherapy Program (GGG) for a half a million grant.
Schunselaar: “Aclarubicin seems to be a potent treatment for many different cancer types. We are first focusing on tumors for which there are few or no available treatments, like uveal melanoma and mesothelioma.”
From left: Ellen Kapiteijn, AG Jochemsen, Gre Luyten, Laurel Schunselaar, Sjaak Neefjes and Frank Speetjens
“It [the course] was very intensive but a lot of fun. The online and on-campus parts all fit well with my experience. My mentor during the extended course had a lot of experience with setting up phase 1 studies and it was very useful to brainstorm with her”, said Schunselaar about her participation in the Clinical Development course.